| Bcl-2 antiapoptotic family proteins and chemoresistance in cancer S Maji, S Panda, SK Samal, O Shriwas, R Rath, M Pellecchia, L Emdad, ... Advances in cancer research 137, 37-75, 2018 | 206 | 2018 |
| Mcl-1 is an important therapeutic target for oral squamous cell carcinomas S Maji, SK Samal, L Pattanaik, S Panda, BA Quinn, SK Das, D Sarkar, ... Oncotarget 6 (18), 16623, 2015 | 59 | 2015 |
| STAT3-and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma S Maji, O Shriwas, SK Samal, M Priyadarshini, R Rath, S Panda, ... Carcinogenesis 40 (1), 173-183, 2019 | 43 | 2019 |
| Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma Y Rajesh, A Biswas, U Kumar, I Banerjee, S Das, S Maji, SK Das, ... Proceedings of the National Academy of Sciences 117 (22), 12324-12331, 2020 | 41 | 2020 |
| MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis SK Das, S Maji, SL Wechman, P Bhoopathi, AK Pradhan, S Talukdar, ... Pharmacological research 155, 104695, 2020 | 40 | 2020 |
| Good's buffer derived highly emissive carbon quantum dots: excellent biocompatible anticancer drug carrier AK Samantara, S Maji, A Ghosh, B Bag, R Dash, BK Jena Journal of Materials Chemistry B 4 (14), 2412-2420, 2016 | 36 | 2016 |
| MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein AK Pradhan, S Maji, SK Das, L Emdad, D Sarkar, PB Fisher Cancer and Metastasis Reviews 39, 769-781, 2020 | 33 | 2020 |
| Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β AK Pradhan, S Maji, P Bhoopathi, S Talukdar, P Mannangatti, C Guo, ... Proceedings of the National Academy of Sciences 118 (21), e2103180118, 2021 | 22 | 2021 |
| Suppression of prostate cancer pathogenesis using an MDA-9/Syntenin (SDCBP) PDZ1 small-molecule inhibitor SK Das, TP Kegelman, AK Pradhan, XN Shen, P Bhoopathi, S Talukdar, ... Molecular Cancer Therapeutics 18 (11), 1997-2007, 2019 | 20 | 2019 |
| Kaposi sarcoma herpes virus latency associated nuclear antigen protein release the G2/M cell cycle blocks by modulating ATM/ATR mediated checkpoint pathway A Kumar, SK Sahu, S Mohanty, S Chakrabarti, S Maji, RR Reddy, AK Jha, ... PLoS One 9 (6), e100228, 2014 | 18 | 2014 |
| Association of p53 codon72 Arg> Pro polymorphism with susceptibility to nasopharyngeal carcinoma: evidence from a case–control study and meta-analysis SK Sahu, S Chakrabarti, SD Roy, N Baishya, RR Reddy, S Suklabaidya, ... Oncogenesis 5 (5), e225-e225, 2016 | 14 | 2016 |
| Insights into the mechanisms of action of MDA-7/IL-24: A ubiquitous cancer-suppressing protein J Modi, A Roy, AK Pradhan, A Kumar, S Talukdar, P Bhoopathi, S Maji, ... International Journal of Molecular Sciences 23 (1), 72, 2021 | 12 | 2021 |
| SARI inhibits growth and reduces survival of oral squamous cell carcinomas (OSCC) by inducing endoplasmic reticulum stress M Priyadarshini, S Maji, SK Samal, R Rath, J Li, SK Das, L Emdad, ... Life Sciences 287, 120141, 2021 | 9 | 2021 |
| Theranostic tripartite cancer terminator virus for cancer therapy and imaging P Bhoopathi, AK Pradhan, S Maji, SK Das, L Emdad, PB Fisher Cancers 13 (4), 857, 2021 | 7 | 2021 |
| MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis S Maji, AK Pradhan, A Kumar, P Bhoopathi, P Mannangatti, C Guo, ... Proceedings of the National Academy of Sciences 120 (45), e2307094120, 2023 | 4 | 2023 |
| Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor AK Pradhan, P Bhoopathi, S Maji, A Kumar, C Guo, P Mannangatti, J Li, ... Frontiers in Oncology 12, 812560, 2022 | 3 | 2022 |
| Dual targeting of the PDZ1 and PDZ2 domains of MDA-9/Syntenin inhibits melanoma metastasis AK Pradhan, J Modi, S Maji, A Kumar, P Bhoopathi, P Mannangatti, C Guo, ... Molecular Cancer Therapeutics 22 (10), 1115-1127, 2023 | 2 | 2023 |
| Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity P Bhoopathi, A Kumar, AK Pradhan, S Maji, P Mannangatti, JJ Windle, ... Journal for Immunotherapy of Cancer 11 (11), 2023 | 2 | 2023 |
| Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus P Bhoopathi, P Mannangatti, AK Pradhan, A Kumar, S Maji, FF Lang, ... Journal of Cellular Physiology, 2024 | 1 | 2024 |
| Conversion of a Non-Cancer-Selective Promoter into a Cancer-Selective Promoter P Bhoopathi, AK Pradhan, A Kumar, S Maji, P Mannangatti, X Deng, ... Cancers 14 (6), 1497, 2022 | 1 | 2022 |
anjan kumar pradhanvirginia commonwealth universityVerified email at vcu.edu
